This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bakalov, V. K. Articles by Bondy, C. A. Search for Related Content PubMed PubMed Citation Articles by Bakalov, V. K. Articles by Bondy, C. A.

Growth Hormone Therapy and Bone Mineral Density in Turner Syndrome

Developmental Endocrinology Branch (V.K.B., P.L.V., J.B., C.A.B.), National Institute of Child Health and Human Development, and Warren G. Magnuson Clinical Center Radiology Department (J.C.R.), National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Vladimir K. Bakalov, M.D., 10 Center Drive, Building 10/10N262, National Institutes of Health, Bethesda, Maryland 20892. E-mail: bakalov{at}mail.nih.gov.

In a previous report, preliminary data showed a significant reduction in cortical bone mineral density (BMD) in women with Turner syndrome that had been treated with GH compared with women with Turner syndrome that had not been treated. To clarify this point, we have investigated the effects of GH treatment at multiple sites in this case-control, cross-sectional study. There were 23 women per group, who were similar in age, height, body mass index, estrogen use, and ethnic makeup. Median age (range) at start and duration of GH treatment was 9 (3–17) and 5 (2–9) yr, respectively. GH-treated women had a slightly greater (8%, P = 0.03) width of the radial shaft, but otherwise there were no significant differences between groups in bone dimensions or BMD at the distal radius, lumbar spine, or femoral neck. Furthermore, regression analysis in a linear model including independent variables of age, age at diagnosis, body mass index, presence of spontaneous puberty, and GH use confirmed that GH use did not contribute to variation in BMD.

This article has been cited by other articles:

				M. Ari, V. K. Bakalov, S. Hill, and C. A. Bondy The Effects of Growth Hormone Treatment on Bone Mineral Density and Body Composition in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4302 - 4305. [Abstract] [Full Text] [PDF]